Evaluation of Pharmacotherapy for Common Medical Conditions in Pregnancy

Purpose Two new scales, CORECTS and PUQE-24 are introduced and validated, and the safety and effectiveness of Proctofoam-HC® in pregnancy is demonstrated. Method 315 of Motherisk NVP patients provided information on five clinical parameters as well as PUQE scores. 28 patients visiting a proctologist...

Full description

Bibliographic Details
Main Author: Ebrahimi, Neda
Other Authors: Koren, Gideon
Language:en_ca
Published: 2011
Subjects:
Online Access:http://hdl.handle.net/1807/30581
Description
Summary:Purpose Two new scales, CORECTS and PUQE-24 are introduced and validated, and the safety and effectiveness of Proctofoam-HC® in pregnancy is demonstrated. Method 315 of Motherisk NVP patients provided information on five clinical parameters as well as PUQE scores. 28 patients visiting a proctologist were graded for the severity of anal conditions by a proctologist before administering CORECTS. Pre and postnatal interviews were conducted with 204 pregnant women prescribed Proctofoam-HC®. Results Strong correlations were found between the following: PUQE-24 scores and parameters of well-being, hospitalization, and multivitamin intake; bleeding and pain components of CORECTS and the proctologist’s grade.There was no significant difference between mean birth weight of Proctofoam-HC® treated and comparison groups. There was a significant reduction in all symptoms of hemorrhoids. Conclusion PUQE-24 and CORECTS are the first validated scales used to assess the severity of NVP and hemorrhoids. Proctofoam-HC® is safe and effective for use in pregnancy.